Function of cell‑cycle regulators in predicting silent pituitary adenoma progression following surgical resection

Park,Sung Hyun; Jang,Ji Hwan; Lee,Young Min; Kim,Joon Soo; Kim,Kyu Hong; Kim,Young Zoon

doi:10.3892/ol.2017.7117

Function of cell‑cycle regulators in predicting silent pituitary adenoma progression following surgical resection

Authors:
- Sung Hyun Park
- Ji Hwan Jang
- Young Min Lee
- Joon Soo Kim
- Kyu Hong Kim
- Young Zoon Kim
View Affiliations

Affiliations: Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Gyeongnam 51353, Republic of Korea
Published online on: October 2, 2017 https://doi.org/10.3892/ol.2017.7117
Pages: 7121-7130
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the use of cell‑cycle regulators for predicting the progression of silent pituitary adenoma (SPA) following surgical resection, via immunohistochemical analysis of tumor samples obtained by surgical resection. The medical records of patients diagnosed with SPA between January 2000 and December 2013 in the Samsung Changwon Hospital, Sungkyunkwan University School of Medicine (Changwon, South Korea) were reviewed. Immunohistochemical staining was performed on sections of the archived, paraffin‑embedded tissues obtained by surgery, with all tissues stained for cell‑cycle regulatory proteins p16, p15, p21, cyclin‑dependent kinase (CDK)4, CDK6, retinoblastoma protein (pRb) and cyclin D1, as well as E3 ubiquitin‑protein ligase mib1 (MIB‑1) antigen and p53. The primary end‑point was to investigate the expression of cell‑cycle regulatory proteins in SPA. The secondary end‑point was to estimate the progression‑free survival of patients with SPA following surgical resection and to identify its association with the expression of cell‑cycle regulatory proteins. Of the 127 SPA samples, 44 (34.6%) were from patients with progression during a mean follow‑up period of 62.4 months (range, 24.2‑118.9 months). Immunohistochemical overexpression was identified in 61 samples (48.0%) for p16, 38 samples (29.9%) for p15, 19 samples (15.0%) for p21, 49 samples (38.6%) for CDK4, 17 samples (13.4%) for CDK6, 57 samples (44.9%) for pRb and in 65 samples (51.2%) for cyclin D1. Multivariate analysis revealed that null cell adenoma [95% confidence interval (CI), 0.276‑0.808], somatotroph SPAs (95% CI, 1.296‑3.121), corticotroph SPAs (95% CI, 1.811‑4.078), pluripotent SPAs (95% CI, 2.264‑5.194), decreased expression of p16 (95% CI, 2.724‑5.588), overexpression of pRb (95% CI, 2.557‑5.333), cyclin D1 (95% CI, 1.894‑4.122) and MIB‑1 (95% CI, 1.561‑4.133), increased mitotic index (95% CI, 1.228‑4.079), increased p53 expression (95% CI, 1.307‑4.065) and invasion into the cavernous sinus (95% CI, 3.842‑7.502) predicted SPA progression following resection. The results of the present study suggested that specific cell‑cycle regulators, including p16, cyclin D1 and pRb, were associated with SPA progression.

View Figures

View References

1	Kovacs K, Horvath E and Vidal S: Classification of pituitary adenomas. J Neurooncol. 54:121–127. 2001. View Article : Google Scholar : PubMed/NCBI
2	Mayson SE and Snyder PJ: Silent pituitary adenomas. Endocrinol Metab Clin North Am. 44:79–87. 2015. View Article : Google Scholar : PubMed/NCBI
3	Fernandez A, Karavitaki N and Wass JA: Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 72:377–382. 2010. View Article : Google Scholar : PubMed/NCBI
4	Raappana A, Koivukangas J, Ebeling T and Pirilä T: Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab. 95:4268–4275. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mayson SE and Snyder PJ: Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol. 117:429–436. 2014. View Article : Google Scholar : PubMed/NCBI
6	Syro LV, Rotondo F, Ramirez A, Di Ieva A, Sav MA, Restrepo LM, Serna CA and Kovacs K: Progress in the diagnosis and classification of pituitary adenomas. Front Endocrinol (Lausanne). 6:972015.PubMed/NCBI
7	Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME and Singer W: Silent corticotropic adenomas of the human pituitary gland: A histologic, immunocytologic, and ultrastructural study. Am J Pathol. 98:617–638. 1980.PubMed/NCBI
8	Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, Laws ER Jr and Singer W: A novel type of pituitary adenoma: Morphological features and clinical correlations. J Clin Endocrinol Metab. 66:1111–1118. 1988. View Article : Google Scholar : PubMed/NCBI
9	Klibanski A: Nonsecreting pituitary tumors. Endocrinol Metab Clinic North Am. 16:793–804. 1987.
10	Randall RV, Scheithauer W and Laws ER Jr: Hormone-containing, non-secreting pituitary tumors: Clinically silent monohormonal pituitary adenomas. Trans Am Clin Climatol Assoc. 96:98–103. 1985.PubMed/NCBI
11	Scheithauer BW, Kovacs KT, Laws ER Jr and Randall RV: Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 65:733–744. 1986. View Article : Google Scholar : PubMed/NCBI
12	Landolt AM, Shibata T and Kleihues P: Growth rate of human pituitary adenomas. J Neurosurg. 67:803–806. 1987. View Article : Google Scholar : PubMed/NCBI
13	Knosp E, Kits K and Perneczky A: Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery. 25:927–930. 1989. View Article : Google Scholar : PubMed/NCBI
14	Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P and Giovanelli M: Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long-term follow-up results. Neurosurgery. 47:1313–1319. 2000. View Article : Google Scholar : PubMed/NCBI
15	Yonezawa K, Tamaki N and Kokunai T: Clinical features and growth fractions of pituitary adenomas. Surg Neurol. 48:494–500. 1997. View Article : Google Scholar : PubMed/NCBI
16	Malumbres M and Barbacid M: To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer. 1:222–231. 2001. View Article : Google Scholar : PubMed/NCBI
17	Srivastava V, Patel B, Kumar M, Shukla M and Pandey M: Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. Asian Pac J Cancer Prev. 14:2711–2715. 2013. View Article : Google Scholar : PubMed/NCBI
18	Cho HY, Cho SW, Kim SW, Shin CS, Park KS and Kim SY: Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 72:648–653. 2010. View Article : Google Scholar : PubMed/NCBI
19	Knosp E, Steiner E, Kitz K and Matula C: Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 33:610–618. 1993. View Article : Google Scholar : PubMed/NCBI
20	Shim JH, Song YJ, Kim DC, Park MK, Choi SS and Kim KU: Silent adenomas of pituitary gland: It's immunohistochemical features and clinical characteristics. J Korean Neurosurg Soc. 40:330–335. 2006.
21	Eng J: Receiver operating characteristic analysis: A primer. Acad Radiol. 12:909–916. 2005. View Article : Google Scholar : PubMed/NCBI
22	Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC and Wu ZB: Natural history of postoperative nonfunctioning pituitary adenomas: A systematic review and meta-analysis. Neuroendocrinology. 96:333–342. 2012. View Article : Google Scholar : PubMed/NCBI
23	Kirsch M, Mörz M, Pinzer T, Schackert HK and Schackert G: Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer. 48:143–154. 2009. View Article : Google Scholar : PubMed/NCBI
24	Gayed BA, Youssef RF, Bagrodia A, Kapur P, Darwish OM, Krabbe LM, Sagalowsky A, Lotan Y and Margulis V: Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. J Urol. 190:1662–1667. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N and Watanabe M: Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol. 98:60–66. 2008. View Article : Google Scholar : PubMed/NCBI
26	Guo LL, Gao P, Wu YG, Jian WC, Hao CY, Li H and Lin XY: Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53. Arch Med Res. 38:846–852. 2007. View Article : Google Scholar : PubMed/NCBI
27	Morgan D, Murray A, Hunt T and Nurse P: The Cell Cycle and Programmed Cell DeathAlberts B, Johnson A, Lewis J, Raff M, Roberts K and Walter P: Molecular Biology of the Cell. Garland Science; New York: pp. 983–1026. 2002
28	Horvath E and Kovacs K: The AdenohypophysisFunctional Endocrine Pathology. Kovacs K and Asa SL: Blackwell; Boston, MA: pp. 245–281. 1990